Quest Diagnostics Incorporated (NYSE:DGX) Holdings Raised by Integrated Advisors Network LLC

Integrated Advisors Network LLC grew its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 13.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,157 shares of the medical research company’s stock after purchasing an additional 259 shares during the period. Integrated Advisors Network LLC’s holdings in Quest Diagnostics were worth $297,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Altshuler Shaham Ltd purchased a new stake in shares of Quest Diagnostics during the fourth quarter valued at $26,000. BKM Wealth Management LLC purchased a new stake in Quest Diagnostics in the 4th quarter worth about $29,000. VisionPoint Advisory Group LLC lifted its stake in Quest Diagnostics by 100.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after acquiring an additional 109 shares in the last quarter. Alaska Permanent Fund Corp lifted its stake in Quest Diagnostics by 79.3% in the 4th quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock worth $33,000 after acquiring an additional 107 shares in the last quarter. Finally, MCF Advisors LLC lifted its stake in Quest Diagnostics by 179.8% in the 4th quarter. MCF Advisors LLC now owns 291 shares of the medical research company’s stock worth $40,000 after acquiring an additional 187 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Price Performance

Shares of NYSE:DGX opened at $137.32 on Wednesday. Quest Diagnostics Incorporated has a 1-year low of $119.59 and a 1-year high of $145.62. The firm has a market capitalization of $15.25 billion, a PE ratio of 18.48, a PEG ratio of 2.99 and a beta of 0.90. The business’s 50 day moving average is $137.52 and its 200-day moving average is $133.66. The company has a current ratio of 0.97, a quick ratio of 0.89 and a debt-to-equity ratio of 0.59.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.18. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The company had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter last year, the firm earned $2.04 EPS. Quest Diagnostics’s revenue for the quarter was up 1.7% compared to the same quarter last year. Sell-side analysts predict that Quest Diagnostics Incorporated will post 8.79 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 22nd. Investors of record on Monday, July 8th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 2.18%. The ex-dividend date is Monday, July 8th. Quest Diagnostics’s dividend payout ratio is 40.38%.

Analysts Set New Price Targets

DGX has been the subject of a number of recent research reports. UBS Group raised their price target on Quest Diagnostics from $139.00 to $146.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Truist Financial raised their price target on Quest Diagnostics from $145.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, April 24th. JPMorgan Chase & Co. increased their price objective on Quest Diagnostics from $152.00 to $155.00 and gave the company a “neutral” rating in a report on Thursday, May 30th. StockNews.com raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Saturday. Finally, SVB Leerink began coverage on Quest Diagnostics in a report on Monday, February 26th. They set a “market perform” rating and a $135.00 price objective on the stock. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $146.67.

Insider Activity at Quest Diagnostics

In related news, SVP Karthik Kuppusamy sold 1,760 shares of the business’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $140.00, for a total value of $246,400.00. Following the sale, the senior vice president now owns 13,435 shares of the company’s stock, valued at approximately $1,880,900. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.79% of the stock is owned by insiders.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.